Multiple Sclerosis Phase III-IV Clinical Trial Outcomes, 2008-2024

ClinicalTrials.gov data on 282 late-stage multiple sclerosis drug trials conducted from 2008 to 2024. The dataset, created by figshare admin karger, includes analysis of trial outcomes, durations, and failure reasons, with 25.2% of trials classified as failed.

Use Cases

• Predicting clinical trial failure risk based on trial characteristics like number of participating centers
• Analyzing the impact of recruitment strategies on trial success rates
• Identifying factors associated with trial duration and early termination
• Studying reasons for trial failure, such as business decisions or logistical problems

Strengths

• Covers 282 clinical trials and 62 experimental drugs, providing a substantive sample for analysis
• Includes specific metrics like average trial duration (17.8 vs. 28.2 months) and failure rate (25.2%)
• Data sourced from ClinicalTrials.gov and supplemented with investigator contact for missing information

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is small (96.5 KB), indicating limited scope or summary-level data

Provenance

Source

ClinicalTrials.gov

Collection Method

Searched for phase III and IV MS drug trials, classified outcomes, and used Kaplan-Meier and logistic regression analysis.

Time Range

2008-2024

Freshness

Last updated 2026-04-15 07:55:17; freshness should be verified

Geography

null